20-Year Experience with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Sarcomatosis DOI Creative Commons

Antonios-Apostolos Tentes,

Dimitrios Kyziridis, Apostolos Kalakonas

et al.

Archives of Oncology and Cancer Therapy, Journal Year: 2024, Volume and Issue: 4(1), P. 25 - 35

Published: Jan. 1, 2024

Abstract Background-Aims: About 80-90% of Soft Tissue Sarcomas (STS) patients develop peritoneal sarcomatosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been used in the treatment sarcomatosis but their role has not clearly defined. The purpose study is presentation experience with CRS plus HIPEC review literature. Patients-Methods: All treated from 2004-2024 were retrospectively reviewed. Clinical histopathologic variables correlated to survival, recurrence, morbidity. Results: Thirty-one patients, mean age 59.3+15 (24-93) years underwent 42 cytoreductive surgical operations. was 33 cases. CC-0 possible 90.6%. 90 days hospital mortality zero. morbidity rate 24.3% severe complications recorded 7.3%. 10-year survival disease free 78% 76% respectively.The median follow-up time 26+27 (2-128) months, 15 months respectively. recurrence 53.5%. > 65 identified as an independent variable survival. No identified. Conclusion: A high proportion may undergo complete cytoreduction. It appears that some subtypes be offered significant benefit CRS.The heterogeneity histopathology, rarity disease, do allow us draw definitive conclusions. Further studies are required understand define proper Keywords: Surgery, HIPEC, Peritoneal Sarcomatosis, Survival, Recurrence, Morbidity. Impact Employee Compensation Benefits on Operating Performance This work licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Copyright © Author(s) retain copyright this article.

Language: Английский

Leiomyosarcoma of the abdomen and retroperitoneum; a systematic review DOI Creative Commons

Mari Nanna Øines,

Henry Smith, Louise Preisler

et al.

Frontiers in Surgery, Journal Year: 2024, Volume and Issue: 11

Published: July 17, 2024

Background Intraabdominal and retroperitoneal leiomyosarcomas are rare cancers, which cause significant morbidity mortality. Symptoms, treatment follow up differs from other proper diagnosis of intraabdominal is utmost importance. We performed a systematic review to collect summarize available evidence for these tumours. Methods literature search Pubmed the earliest entry possible, until January 2021. Our phrase was (((((colon) OR (rectum)) (intestine)) (abdomen)) (retroperitoneum)) AND (leiomyosarcoma). All hits were evaluated by two authors. Results predefined identified 1983 hits, we selected 218 retrieved full-text copies these. 144 studies included in review. Discussion This summarizes current knowledge on non-uterine abdominal leiomyosarcomas. The has revealed lack high-quality evidence, randomized clinical trials. There great need more substantial research area abdomen retroperitoneum. Systematic Review Registration PROSPERO, identifier, CRD42023480527.

Language: Английский

Citations

2
Comprehensive treatment strategy for improving surgical resection rate of retroperitoneal sarcomas: a histology-specific approach narrative review DOI Creative Commons
Dorian Yarih García-Ortega

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 7, 2024

Retroperitoneal sarcoma (RPS) represents a rare and heterogeneous group of malignancies, posing significant challenges in evaluation management. Surgery, the cornerstone RPS treatment, critically depends on complete resection for favorable prognosis. The extent is crucial determinant local control survival. This review delves into evolution multidisciplinary management localized RPS, highlighting imperative to adapt surgical strategies tumor histology, location, patient functional status. We explore principles compartmental surgery—an extended first-line approach that involves resecting adjacent viscera wide negative margins—and its effectiveness across different histological subtypes more limited resections other types. Particular emphasis placed heterogeneity disease, as various exhibit distinct biological behaviors. necessitates shift away from one-size-fits-all treatment approach. analyzes role strategies, focusing type location. Additionally, potential benefits (neo)adjuvant treatments, such radiotherapy chemotherapy, are examined, recognizing their specific indications limitations. comprehensive consolidates recent data complementary therapies, advocating personalized tailored histology. As understanding molecular genetic underpinnings continues evolve, so will effective management, underscoring need global collaboration among specialists this field enhance our collective knowledge methodologies.

Language: Английский

Citations

2
A Rare Case of Dedifferentiated Liposarcoma with Osteosarcomatous Differentiation-Diagnostic and Therapeutic Challenges DOI Creative Commons
Patrycja Sosnowska‐Sienkiewicz, Przemysław Mańkowski, Honorata Stadnik

et al.

Diseases, Journal Year: 2023, Volume and Issue: 12(1), P. 6 - 6

Published: Dec. 25, 2023

Liposarcomas are the most common of all sarcomas. A well-differentiated liposarcoma can transform into a dedifferentiated with myogenic, osteo- or chondrosarcomatous heterologous differentiation. Genomic amplification

Language: Английский

Citations

4
Metastatic dedifferentiated liposarcoma of the mediastinum with osteosarcomatous differentiation: A case report DOI Creative Commons
Cong Hu,

S H Nong,

Aihua Liu

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(49), P. e40748 - e40748

Published: Dec. 6, 2024

Liposarcoma is a malignant tumor of adipocytic differentiation that rarely arises within the mediastinum. Most existing data available comes from scattered case reports and few small series. A 51-year-old man was admitted with cough sputum accompanied by fever. X-ray CT showed bulky anterior mediastinal mass initially misdiagnosed as teratoma. PET/CT demonstrated lesion on location showing area moderately intense uptake. After surgical excision, histopathological examination via hematoxylin eosin first revealed diagnosis undifferentiated tumors. The results immunohistochemical evaluations were follows: P63 (scattered +), VIMENTIN (giant cell CD68 (KPI; giant SMA (-), Ki-67 (Li: 50%). Molecular pathology: MDM2 gene status (+) amplification. final dedifferentiated liposarcoma osteosarcomatous differentiation. patient underwent left resection, upper lobe wedge resection postoperative chemotherapy. Mediastinal recurrences chest wall metastases occurred quickly before second round chemotherapy 2 months later. Four after surgery, died. This paper presents in rare location: Correct importance for appropriate choice therapy. Clinicians should be aware presence mediastinum enhancing treatment management strategies affected patients.

Language: Английский

Citations

1
Case report and literature review: Conversion surgery for initially unresectable huge retroperitoneal liposarcoma after preoperative radiotherapy DOI Creative Commons
Sarah Hsin Cheng, Yen‐Shuo Huang, Hsin-Hua Lee

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 12

Published: Jan. 6, 2023

Background Retroperitoneal liposarcoma (RPLS) is a rare malignancy that notorious for recurrence. Surgical resection with clean margin the current treatment of choice. However, owing to large retroperitoneal space, RPLSs often grow significant sizes before being diagnosed. Neoadjuvant and adjuvant therapies have potentials improve long term outcome. Case presentation A 55-year-old Han Chinese male presented general surgery department one-year history abdominal fullness one-week palpable right inguinal mass. At first, he was diagnosed incarcerated hernia. computer tomography (CT) biopsy confirmed his final diagnosis be well-differentiated liposarcoma, cT2bN0M0, stage IIb. The tumor, which measured 44.5cm in maximum diameter, too primary surgical resection. radiotherapy 70 Gy 35 fractions delivered shrunk target volume from 6300 cc 4800 cc, as observed middle course. testicular mass also received 70Gy/35Fx. Conversion performed after radiotherapy. Unfortunately, due residual chemotherapy consisting AIM (ifosfamide, Mesna, doxorubicin) MAID (Mesna, doxorubincin, ifosfamide, dacarbazine) regimens were administered sequentially. Afterward, debulking conducted, plus another 18 cycles ifosfamide monotherapy when tumor still seen on CT. Since completion chemotherapy, patient has been cancer free no evidence recurrence more than 26 months. Conclusion Despite conflicting literature, our case supports use high dose neoadjuvant treating large, unresectable RPLSs. It highlights importance using individualized, multidisciplinary approach achieving cure tumors.

Language: Английский

Citations

3
Giant retroperitoneal liposarcoma measuring 27 × 29 × 36 cm: a case report DOI Creative Commons

Catalina Gutu,

Valentin Butnari, Victor Schiopu

et al.

Journal of Surgical Case Reports, Journal Year: 2023, Volume and Issue: 2023(1)

Published: Jan. 1, 2023

Retroperitoneal tumors are rare neoplasms that can reach great dimensions due to a slow growth pattern. Although these rarely metastasize, they have risk of recurrence, and majority times lesions challenge for the surgeon. We report case 63-year-old woman who presented with symptoms large bowel obstruction was diagnosed heterogenous mass located in retroperitoneal space. The fine needle biopsy revealed histology liposarcoma. purpose this article is our approach management kind tumor. Tumor size (27.1 × 29.1 36.1 cm) involvement adjacent organs us order safe oncological margins. In cases, recurrence high; therefore, patient should be screened at 6, 12 24 months post procedure. Chemotherapy or radiotherapy tumor not yet defined, if operable, surgery treatment choice.

Language: Английский

Citations

3
Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study DOI
Gabriella N. Tortorello,

Eric H. Li,

Cimarron E. Sharon

et al.

Annals of Surgical Oncology, Journal Year: 2023, Volume and Issue: 30(11), P. 6886 - 6893

Published: July 24, 2023

Language: Английский

Citations

3
Retroperitoneal synovial sarcoma DOI Open Access
Aleksandr A. Lisitsyn,

V. P. Zemlyanoy,

И. Е. Коткас

et al.

HERALD of North-Western State Medical University named after I I Mechnikov, Journal Year: 2024, Volume and Issue: 15(4), P. 81 - 88

Published: Jan. 13, 2024

Synovial sarcoma of the retroperitoneum is a rare and aggressive tumor. In some cases, differential diagnosis between retroperitoneal adrenocortical cancer difficult due to similar clinical intrascopic manifestations these neoplasms. The final established based on results histological, immunohistochemical genetic studies. most important step in treatment synovial complete removal However, despite radical nature intervention, incidence local relapse metastasis remains high. AIM: conduct retrospective analysis parameters operated patients with retroperitoneum. This study aimed at studying examination surgical space who were hospitalized E.E. Eichwald Clinic department North-Western State Medical University named after. I.I. Mechnikov. assessed for hormonal status using an immunoassay determine levels adrenocorticotropic hormone, cortisol, aldosterone, renin, normetanephrine metanephrine blood, dexamethasone suppression test has been performed dose 1 mg. High-performance liquid chromatography determined 6 glucocorticoids blood serum: cortisone, corticosterone, 11-deoxycorticosterone, 11-dehydrocorticosterone, 11-deoxycortisol. urine steroid profile was studied all gas chromatography-mass spectrometry. All underwent computed tomography abdominal organs contrast, morphological removed material. material fixed 10% neutral buffered formalin. pieces then subjected standard wiring followed by embedding paraffin. Sections 2–3 microns thick prepared from resulting blocks stained hematoxylin eosin. Immunohistochemical studies paraffin sections. A panel monoclonal antibodies used: protein S-100 (poly), pancytokeratin (AE1/AE3), EMA, cytokeratin-8, -18, chromogranin A, synaptophysin, α-inhibin, SOX-10, CD99, TLE-1, bcl- 2, GATA-3. Postoperative outcomes follow-up according information medical records data obtained telephone conversation each patient. Statistical processing not out cases disease.

Language: Английский

Citations

0
The Use of Extracorporeal Circulation to Facilitate the Resection of a Large Retroperitoneal Sarcoma With Major Vessel Involvement: A Single-Center Review of 20 Cases DOI
Reza Yusoff, James Preuss, William M. Weightman

et al.

Journal of Cardiothoracic and Vascular Anesthesia, Journal Year: 2023, Volume and Issue: 37(7), P. 1223 - 1229

Published: March 12, 2023

Language: Английский

Citations

1
The Role of Surgery in Oligometastatic Retroperitoneal Sarcoma DOI Creative Commons
Lindsay A. Janes, Christina V. Angeles

Current Oncology, Journal Year: 2023, Volume and Issue: 30(6), P. 5240 - 5250

Published: May 24, 2023

Retroperitoneal sarcomas are extremely rare, comprising <15% of primary sarcomas. Distant metastasis occurs in about 20% cases, with pulmonary and hepatic as the most common sites hematogenous spread. Although surgical resection is well established main treatment localized disease, there limited guidelines for intra-abdominal distant metastases. There inadequate systemic options patients metastatic sarcoma, thereby necessitating consideration carefully selected patients. Key points to consider include tumor biology, patient fitness co-morbidities, overall prognosis, goals care. Multidisciplinary sarcoma board discussion each case an essential practice order deliver best care these The purpose this review summarize published literature on past present role surgery oligometastatic retroperitoneal inform management difficult disease.

Language: Английский

Citations

1